Xolair’s NEJM Phase III Data: Hope for Multiple Food Allergies
Genentech announced key findings from Stage 1 of the NIH-sponsored Phase III OUtMATCH study, published in the New England...
Silence Therapeutics Nabs $10M From AstraZeneca Phase 1 Start
Silence Therapeutics plc, a biotechnology company specializing in RNA interference (RNAi) therapies, has announced the initiation of a Phase...
The Enhanced eConsent Evolution: A New Era for Trials
A groundbreaking proof-of-concept study conducted by Medable and the Duke BASE Lab unveiled electronic informed consent (eConsent) solutions in...
Worldwide Clinical Trials Trials Upgrades Unit Pharmacy for Client Efficiency
Worldwide Clinical Trials has enhanced its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, with a significant expansion completed...
2024 SCOPE Summit Insights: Navigating New Clinical Trial Change
The 2024 SCOPE Summit catalyzed thought-provoking dialogue on the transformative currents sweeping through the clinical trials landscape. Hassan Kadhim,...
Tagrisso’s Phase III Success in Unresectable EGFR Lung Cancer
AstraZeneca’s TAGRISSO® (osimertinib) has shown positive results in the LAURA Phase III trial, demonstrating a significant and clinically meaningful...
EU Nods Pfizer’s Velsipity® for Ulcerative Colitis
Pfizer Inc. announced that the European Commission has approved VELSIPITY® (etrasimod) for the treatment of patients aged 16 and...
eCOA: Should Sponsors Give Clinical Sites More Control?
Electronic Clinical Outcome Assessments (eCOA) have significantly advanced clinical trials, offering a more accurate and efficient data collection method....
How To Overcome Large-Scale Clinical Trial EDC Migration
In an unprecedented move within the life sciences industry, Veeva announced the successful migration of 25 clinical studies for...
“Time is Life” – Pfizer Mantra for Revolutionizing Clinical Trials
February 12, 2024, marked a significant moment at the SCOPE Summit 2024 as Rob Goodwin, Sr. VP and Head...